The role of self-monitoring of blood glucose in patients treated with SGLT-2 inhibitors: A European expert recommendation

Oliver Schnell, Hasan Alawi, Tadej Battelino, Antonio Ceriello, Peter Diem, Anne Marie Felton, Kari Harno, Ilhan Satman, Bruno Vergès

Research output: Contribution to journalArticle

Abstract

The role for the novel treatment approach of sodium-glucose cotransporter-2 (SGLT-2) in type 2 diabetes is increasing. Structured self-monitoring of blood glucose (SMBG), based on a less intensive and a more intensive scheme, may contribute to an optimization of SGLT-2 inhibitor based treatment. The current expert recommendation suggests individualized approaches of SMBG, using simple and clinically applicable schemes. Potential benefits of SMBG in SGLT-2 inhibitor based treatment approaches are early assessment of treatment success or failure, timely modification of treatment, detection of hypoglycemic episodes, assessment of glucose excursions, and support of diabetes management and education. The length and frequency of SMBG should depend on the clinical setting and the quality of metabolic control.

Original languageEnglish
Pages (from-to)783-790
Number of pages8
JournalJournal of diabetes science and technology
Volume8
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

Sodium-Glucose Transport Proteins
Blood Glucose Self-Monitoring
Glucose
Blood Glucose
Blood
Sodium
Monitoring
Medical problems
Therapeutics
Hypoglycemic Agents
Quality Control
Education
Type 2 Diabetes Mellitus

Keywords

  • Hypoglycemia
  • Self-monitoring of blood glucose
  • SGLT-2 inhibitors
  • SMBG
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Bioengineering
  • Biomedical Engineering
  • Medicine(all)

Cite this

The role of self-monitoring of blood glucose in patients treated with SGLT-2 inhibitors : A European expert recommendation. / Schnell, Oliver; Alawi, Hasan; Battelino, Tadej; Ceriello, Antonio; Diem, Peter; Felton, Anne Marie; Harno, Kari; Satman, Ilhan; Vergès, Bruno.

In: Journal of diabetes science and technology, Vol. 8, No. 4, 2014, p. 783-790.

Research output: Contribution to journalArticle

Schnell, Oliver ; Alawi, Hasan ; Battelino, Tadej ; Ceriello, Antonio ; Diem, Peter ; Felton, Anne Marie ; Harno, Kari ; Satman, Ilhan ; Vergès, Bruno. / The role of self-monitoring of blood glucose in patients treated with SGLT-2 inhibitors : A European expert recommendation. In: Journal of diabetes science and technology. 2014 ; Vol. 8, No. 4. pp. 783-790.
@article{68705fdbe13a4feabdd89ab470d4ca9e,
title = "The role of self-monitoring of blood glucose in patients treated with SGLT-2 inhibitors: A European expert recommendation",
abstract = "The role for the novel treatment approach of sodium-glucose cotransporter-2 (SGLT-2) in type 2 diabetes is increasing. Structured self-monitoring of blood glucose (SMBG), based on a less intensive and a more intensive scheme, may contribute to an optimization of SGLT-2 inhibitor based treatment. The current expert recommendation suggests individualized approaches of SMBG, using simple and clinically applicable schemes. Potential benefits of SMBG in SGLT-2 inhibitor based treatment approaches are early assessment of treatment success or failure, timely modification of treatment, detection of hypoglycemic episodes, assessment of glucose excursions, and support of diabetes management and education. The length and frequency of SMBG should depend on the clinical setting and the quality of metabolic control.",
keywords = "Hypoglycemia, Self-monitoring of blood glucose, SGLT-2 inhibitors, SMBG, Type 2 diabetes",
author = "Oliver Schnell and Hasan Alawi and Tadej Battelino and Antonio Ceriello and Peter Diem and Felton, {Anne Marie} and Kari Harno and Ilhan Satman and Bruno Verg{\`e}s",
year = "2014",
doi = "10.1177/1932296814534366",
language = "English",
volume = "8",
pages = "783--790",
journal = "Journal of diabetes science and technology",
issn = "1932-2968",
publisher = "Diabetes Technology Society",
number = "4",

}

TY - JOUR

T1 - The role of self-monitoring of blood glucose in patients treated with SGLT-2 inhibitors

T2 - A European expert recommendation

AU - Schnell, Oliver

AU - Alawi, Hasan

AU - Battelino, Tadej

AU - Ceriello, Antonio

AU - Diem, Peter

AU - Felton, Anne Marie

AU - Harno, Kari

AU - Satman, Ilhan

AU - Vergès, Bruno

PY - 2014

Y1 - 2014

N2 - The role for the novel treatment approach of sodium-glucose cotransporter-2 (SGLT-2) in type 2 diabetes is increasing. Structured self-monitoring of blood glucose (SMBG), based on a less intensive and a more intensive scheme, may contribute to an optimization of SGLT-2 inhibitor based treatment. The current expert recommendation suggests individualized approaches of SMBG, using simple and clinically applicable schemes. Potential benefits of SMBG in SGLT-2 inhibitor based treatment approaches are early assessment of treatment success or failure, timely modification of treatment, detection of hypoglycemic episodes, assessment of glucose excursions, and support of diabetes management and education. The length and frequency of SMBG should depend on the clinical setting and the quality of metabolic control.

AB - The role for the novel treatment approach of sodium-glucose cotransporter-2 (SGLT-2) in type 2 diabetes is increasing. Structured self-monitoring of blood glucose (SMBG), based on a less intensive and a more intensive scheme, may contribute to an optimization of SGLT-2 inhibitor based treatment. The current expert recommendation suggests individualized approaches of SMBG, using simple and clinically applicable schemes. Potential benefits of SMBG in SGLT-2 inhibitor based treatment approaches are early assessment of treatment success or failure, timely modification of treatment, detection of hypoglycemic episodes, assessment of glucose excursions, and support of diabetes management and education. The length and frequency of SMBG should depend on the clinical setting and the quality of metabolic control.

KW - Hypoglycemia

KW - Self-monitoring of blood glucose

KW - SGLT-2 inhibitors

KW - SMBG

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84905905504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905905504&partnerID=8YFLogxK

U2 - 10.1177/1932296814534366

DO - 10.1177/1932296814534366

M3 - Article

C2 - 24876442

AN - SCOPUS:84905905504

VL - 8

SP - 783

EP - 790

JO - Journal of diabetes science and technology

JF - Journal of diabetes science and technology

SN - 1932-2968

IS - 4

ER -